A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
You are being asked to participate in this study because you have acute myeloid leukemia (AML) that is either relapsed (has come back) or refractory (has not responded to treatment). The goal of this clinical research study is to compare the effects of the study drug ASP2215 to those of standard-of-care chemotherapies in patients with AML with mutations in the FLT3 gene. The safety of these drugs will also be compared.
Treatment Location: N/A
IRB Review and Approval Date: 05/27/2016
Recruitment Status: Not Accepting
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: